🚨 ESMO 2026 | TOP 10 GYNAE ONCOLOGY TRIALS TO WATCH!
From chemotherapy-free immunotherapy to next-generation ADCs, #ESMO26 could reshape gynaecological oncology!
🔥 My Top 10, by cancer subtype:
🔴 ENDOMETRIAL CANCER
TroFuse-005 (LBA11) | Sacituzumab tirumotecan vs physician’s choice in recurrent/advanced disease.
KEYNOTE-C93 (LBA12) | Pembrolizumab alone vs chemotherapy in 1L dMMR disease. Can we omit chemotherapy?
NRG-GY020 (1239O) | Adjuvant radiotherapy ± pembrolizumab in early-stage dMMR disease.
Sacituzumab tirumotecan + pembrolizumab (1259P) | ADC + immunotherapy in post-platinum pMMR disease.
🔵 OVARIAN CANCER
BEHOLD-1 (LBA41) | Mocertatug rezetecan, a B7-H4 ADC, in platinum-resistant disease.
REJOICE-Ovarian02 (1247RO) | Raludotatug deruxtecan + bevacizumab in platinum-resistant disease.
REJOICE-Ovarian01 (1331P) | Updated efficacy and safety of raludotatug deruxtecan.
BEHOLD-1 biomarker analysis (1248RO) | Which biomarkers predict response to B7-H4 ADC therapy?
🟣 CERVICAL CANCER
CALLA (LBA45) | Tisotumab vedotin + pembrolizumab vs chemotherapy in recurrent/metastatic disease.
EMPOWER-Cervical 1 (1250O) | Cemiplimab-based strategies and long-term outcomes.
⭐ My top 3 to watch:
KEYNOTE-C93 | TroFuse-005 | BEHOLD-1
Which trial has the greatest potential to change your practice?
@ESMO_open @myesmo @ASCO @oncoalert
#ESMO26 #GynOnc #Oncology
2438 浏览 · 30 赞 · 9 转发 · 1 回复
NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer
https://esmocongress.esmo.orgSacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgRaludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Updated results from the phase 2 dose-optimization part of REJOICE-Ovarian01
https://esmocongress.esmo.orgCLARITY-Gastric 02: A randomised phase 3 study of sonesitatug vedotin (Sone-Ve) and capecitabine with or without rilvegostomig in Claudin18.2 positive (CLDN18.2+) advanced or metastatic gastric, gastroesophageal junction, or oesophageal ade
https://esmocongress.esmo.orgINTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.org🚨 ESMO 2026: 15 Trials That Could Change Oncology Practice! From personalized cancer vaccines and bispecific antibodies to next-generation ADCs, major results are coming. 🔥 My Top 15 to Watch: 1. INTerpath-001 | Melanoma 2. SAFFRON | EGFR+ NSCLC 3. Krascendo 1 | KRAS G12C NSCLC 4. DeLLphi-305 | ES-SCLC 5. HARMONi-GI1 | Biliary 6. VOLGA | Bladder 7. DASL-HiCaP | Prostate 8. NATALEE | Breast 9. TRIO-US B-12 TALENT | Breast 10. ENERGIZE | Bladder 11. CLARITY-Gastric 01 | Gastric 12. KEYNOTE-C93 | Endometrial 13. KEYNOTE-B49 | Breast 14. LITESPARK-011 | RCC 15. SigVie-002 | NSCLC 📊 The big question: Which trials will deliver meaningful survival benefits and redefine standards of care? Not every positive trial is practice-changing. 👨⚕️ Oncologists, which trial are you watching most closely? #ESMO26 #Oncology #CancerResearch @ASCO @oncoalert @myesmo @esmo_open在 X 查看被引用的帖子
- E Lambrechts@EgidiusLambrech
@DrRishabhOnco you have a mistake on LBA45
来源：Dr Rishabh Jain · x.com